[{"Assets_0_Q2_USD":627727000.0,"CommonStockSharesOutstanding_0_Q2_shares":101623521.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":104307000.0,"NetIncomeLoss_1_Q2_USD":-16640000.0,"NetIncomeLoss_2_Q2_USD":-36827000.0,"StockholdersEquity_0_Q2_USD":387867000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":21416000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":34053000.0,"Ticker":"SGMO","CIK":"1001233","name":"SANGAMO THERAPEUTICS, INC","OfficialName":"Sangamo Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"750923571.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180808"}]